Exchange: NASDAQ·Updated 07:57 PM EDT

PPBTPurple Biotech Ltd - ADR

$1.70
$0.06
(3.41%)
Today
Closed $1.70
$0.0099
(0.58%)
After Hours
Mkt Cap$2.76M
Vol35,477.00

About

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
10

Frequently Asked Questions

What is Market Cap of Purple Biotech Ltd - ADR?
What is the 52-week high for Purple Biotech Ltd - ADR?
What is the 52-week low for Purple Biotech Ltd - ADR?
What is Purple Biotech Ltd - ADR stock price today?
What was Purple Biotech Ltd - ADR stock price yesterday?
What is the PE ratio of Purple Biotech Ltd - ADR?
What is the Price-to-Book ratio of Purple Biotech Ltd - ADR?
What is the 50-day moving average of Purple Biotech Ltd - ADR?
How many employees does Purple Biotech Ltd - ADR have?